Brenda Sandmaier
Fred Hutch/University of Washington Cancer Consortium · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium · Fred Hutchinson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Brenda Sandmaier as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:29 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT01300572 · Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDSFred Hutchinson Cancer Center · completed · Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT01252667 · Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell TransplantFred Hutchinson Cancer Center · completed · Acute Myeloid Leukemia · principal investigator
- Ph2NCT01251575 · Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantFred Hutchinson Cancer Center · completed · Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Diffuse Large B-Cell Lymphoma · principal investigator
- Ph3NCT01231412 · Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell TransplantFred Hutchinson Cancer Center · completed · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma · principal investigator
- Ph1NCT00988715 · Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic SyndromeFred Hutchinson Cancer Center · completed · Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome · principal investigator
- Ph1/Ph2NCT00789776 · Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic CancerFred Hutchinson Cancer Center · completed · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma · principal investigator
- Ph2NCT00397813 · Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative DisordersFred Hutchinson Cancer Center · completed · Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome · principal investigator
- Ph1/Ph2NCT00119340 · Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous LeukemiaFred Hutchinson Cancer Center · completed · Leukemia · principal investigator
- Ph2NCT00118352 · Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerFred Hutchinson Cancer Center · completed · Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission · principal investigator
- Ph2NCT00110058 · Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous LeukemiaFred Hutchinson Cancer Center · completed · Leukemia · principal investigator
- Ph2NCT00105001 · Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerFred Hutchinson Cancer Center · completed · Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome, Refractory Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT00096161 · Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell TransplantFred Hutchinson Cancer Center · completed · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia · principal investigator
- N/ANCT00005799 · Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerFred Hutchinson Cancer Center · completed · Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission · principal investigator
- Ph1/Ph2NCT00078858 · Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell TransplantFred Hutchinson Cancer Center · completed · Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission · principal investigator
- Ph3NCT00075478 · Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic CancerFred Hutchinson Cancer Center · completed · Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Aggressive Non-Hodgkin Lymphoma · principal investigator
- Ph1/Ph2NCT00068718 · Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell TransplantFred Hutchinson Cancer Center · completed · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia · principal investigator
- Ph2NCT00045435 · Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in RemissionFred Hutchinson Cancer Center · completed · Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · principal investigator
- Ph2NCT00040846 · Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological MalignanciesFred Hutchinson Cancer Center · completed · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) · principal investigator
- Ph2NCT00003145 · Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid LeukemiaFred Hutchinson Cancer Center · completed · Accelerated Phase of Disease, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive · principal investigator
- Ph1/Ph2NCT00005851 · Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney CancerFred Hutchinson Cancer Center · completed · Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer · principal investigator
- Ph1/Ph2NCT00027820 · Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerFred Hutchinson Cancer Center · completed · Adult Acute Myeloid Leukemia in Remission, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Core B: Pharmaceutical ProductionP01CA078902 · NCI · FRED HUTCHINSON CANCER CENTER · fiscal years 2004 to 2025 · $681,869 awarded in 2025Grant number is on one of their registry trials
- Project 2: Minimal-Intensity Conditioning with Antibody-Targeted Alpha RadiationP01HL122173 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2015 to 2019 · $486,199 awarded in 2019Same name and institution; not confirmed by an ID
- Alpha Emitter Labeled Anti-T Cell Antibody: Targeting Latent HIV Infected CellsR33AI116225 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2016 to 2018 · $346,370 awarded in 2018Same name and institution; not confirmed by an ID
- Alpha Radioimmunotherapy for Lymphoma TreatmentR01CA172582 · NCI · FRED HUTCHINSON CANCER CENTER · fiscal years 2013 to 2018 · $131,173 awarded in 2018Same name and institution; not confirmed by an ID
- Alpha Emitter Labeled Anti-T Cell Antibody: Targeting Latent HIV Infected CellsR21AI116225 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2014 to 2015 · $235,160 awarded in 2015Same name and institution; not confirmed by an ID
- Therapy of Lymphoma/Leukemia with Monoclonal AntibodiesP01CA044991 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2015 · $2,206,479 awarded in 2015Grant number is on one of their registry trials
- Astatine-211 Conditioning for Nonmyeloablative Hematopoietic Stem Cell AllograftsR01CA118940 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2006 to 2010 · $285,649 awarded in 2010Same name and institution; not confirmed by an ID
- Nonmyeloablative Allografts in DLA-haploidentical Dogs: Engraftment and GVHDP01HL036444 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 1996 to 2010 · $419,118 awarded in 2010Same name and institution; not confirmed by an ID
- IMMUNOTHERAPY FOLLOWING TRANSPLANT FOR BREAST CANCERR55CA067112 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 1995 · $84,000 awarded in 1995Same name and institution; not confirmed by an ID
- MECHANISM OF ANTIBODY FACILITATED MARROW ENGRAFTMENTK08CA001483 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 1990 to 1994 · $87,397 awarded in 1994Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Center AdministrationP30CA015704 · NCI · FRED HUTCHINSON CANCER CENTER · PI WENDY LAW · fiscal years 2018 to 2026
- Engineering Effective T cell Immunity to Multiple MyelomaP01CA018029 · NCI · FRED HUTCHINSON CANCER CENTER · PI MADHAV V DHODAPKAR · fiscal years 2018 to 2026Named on NCT01251575, NCT01231412, NCT00397813, NCT00118352, NCT00105001, NCT00005799, NCT00078858, NCT00040846, NCT00027820
Most cited trial papers
Clinical-trial papers with this author name in childhood acute lymphoblastic leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 11:29 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- Cord-Blood Transplantation in Patients with Minimal Residual Disease.N Engl J Med · 2016382 citationsRCR 13.9
- 284 citationsRCR 6.7
- Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.Haematologica · 201175 citationsRCR 2.0